Royal Bank of Canada’s Kyntra Bio KYNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1K | Buy |
138
+1
| +0.7% | +$7 | ﹤0.01% | 7226 |
|
|
2026
Q1 | $1K | Sell |
137
-1
| -0.7% | -$8 | ﹤0.01% | 6862 |
|
|
2025
Q4 | $1K | Buy |
138
+1
| +0.7% | +$10 | ﹤0.01% | 6989 |
|
|
2025
Q3 | $2K | Hold |
137
| – | – | ﹤0.01% | 6877 |
|
|
2025
Q2 | $1K | Buy |
137
+46
| +51% | +$335 | ﹤0.01% | 6878 |
|
|
2025
Q1 | $1K | Buy |
91
+78
| +600% | +$935 | ﹤0.01% | 6658 |
|
|
2024
Q4 | $0 | Buy |
+13
| New | +$121 | ﹤0.01% | 6987 |
|
|
2024
Q3 | – | Sell |
-272
| Closed | -$6K | – | 7027 |
|
|
2024
Q2 | $6K | Sell |
272
-33
| -11% | -$1.02K | ﹤0.01% | 6480 |
|
|
2024
Q1 | $18K | Sell |
305
-885
| -74% | -$38.1K | ﹤0.01% | 5958 |
|
|
2023
Q4 | $26K | Buy |
1,190
+579
| +95% | +$8.73K | ﹤0.01% | 6223 |
|
|
2023
Q3 | $13K | Sell |
611
-964
| -61% | -$37.9K | ﹤0.01% | 6332 |
|
|
2023
Q2 | $107K | Buy |
1,575
+1,324
| +527% | +$548K | ﹤0.01% | 5279 |
|
|
2023
Q1 | $118K | Sell |
251
-582
| -70% | -$308K | ﹤0.01% | 5044 |
|
|
2022
Q4 | $334K | Buy |
833
+740
| +796% | +$283K | ﹤0.01% | 4442 |
|
|
2022
Q3 | $30K | Buy |
93
+29
| +45% | +$9.34K | ﹤0.01% | 5977 |
|
|
2022
Q2 | $17K | Sell |
64
-200
| -76% | -$51.1K | ﹤0.01% | 6178 |
|
|
2022
Q1 | $80K | Sell |
264
-280
| -51% | -$97.6K | ﹤0.01% | 5800 |
|
|
2021
Q4 | $192K | Buy |
544
+246
| +83% | +$76.6K | ﹤0.01% | 5370 |
|
|
2021
Q3 | $76K | Buy |
298
+51
| +21% | +$18.1K | ﹤0.01% | 5895 |
|
|
2021
Q2 | $164K | Sell |
247
-682
| -73% | -$393K | ﹤0.01% | 5240 |
|
|
2021
Q1 | $807K | Sell |
929
-790
| -46% | -$841K | ﹤0.01% | 3779 |
|
|
2020
Q4 | $1.59M | Sell |
1,719
-1,197
| -41% | -$1.26M | ﹤0.01% | 3124 |
|
|
2020
Q3 | $3M | Buy |
2,916
+1,989
| +215% | +$2.14M | ﹤0.01% | 2365 |
|
|
2020
Q2 | $940K | Sell |
927
-14
| -1% | -$13K | ﹤0.01% | 3229 |
|
|
2020
Q1 | $819K | Sell |
941
-60
| -6% | -$59.6K | ﹤0.01% | 3197 |
|
|
2019
Q4 | $1.07M | Buy |
1,001
+51
| +5% | +$52.1K | ﹤0.01% | 3392 |
|
|
2019
Q3 | $879K | Sell |
950
-18
| -2% | -$19.8K | ﹤0.01% | 3447 |
|
|
2019
Q2 | $1.09M | Sell |
968
-107
| -10% | -$117K | ﹤0.01% | 3228 |
|
|
2019
Q1 | $1.46M | Buy |
1,075
+883
| +460% | +$1.2M | ﹤0.01% | 2911 |
|
|
2018
Q4 | $222K | Sell |
192
-90
| -32% | -$101K | ﹤0.01% | 4286 |
|
|
2018
Q3 | $428K | Buy |
282
+75
| +36% | +$116K | ﹤0.01% | 3997 |
|
|
2018
Q2 | $325K | Buy |
207
+14
| +7% | +$18.3K | ﹤0.01% | 4115 |
|
|
2018
Q1 | $222K | Sell |
193
-34
| -15% | -$44.8K | ﹤0.01% | 4267 |
|
|
2017
Q4 | $268K | Sell |
227
-396
| -64% | -$497K | ﹤0.01% | 4240 |
|
|
2017
Q3 | $837K | Buy |
623
+65
| +12% | +$68.5K | ﹤0.01% | 3370 |
|
|
2017
Q2 | $450K | Sell |
558
-404
| -42% | -$281K | ﹤0.01% | 3729 |
|
|
2017
Q1 | $594K | Buy |
962
+544
| +130% | +$331K | ﹤0.01% | 3504 |
|
|
2016
Q4 | $223K | Buy |
418
+124
| +42% | +$61.9K | ﹤0.01% | 4405 |
|
|
2016
Q3 | $152K | Sell |
294
-12
| -4% | -$5.65K | ﹤0.01% | 4597 |
|
|
2016
Q2 | $126K | Sell |
306
-5,997
| -95% | -$2.75M | ﹤0.01% | 4673 |
|
|
2016
Q1 | $3.35M | Sell |
6,303
-2,525
| -29% | -$1.26M | ﹤0.01% | 2075 |
|
|
2015
Q4 | $6.72M | Buy |
8,828
+8,564
| +3,244% | +$5.68M | ﹤0.01% | 1678 |
|
|
2015
Q3 | $145K | Sell |
264
-28
| -10% | -$17K | ﹤0.01% | 4535 |
|
|
2015
Q2 | $171K | Buy |
292
+220
| +306% | +$128K | ﹤0.01% | 4494 |
|
|
2015
Q1 | $57K | Buy |
72
+44
| +157% | +$34.1K | ﹤0.01% | 4910 |
|
|
2014
Q4 | $19K | Buy |
+28
| New | +$18K | ﹤0.01% | 5416 |
|
Other funds holding KYNB
AC
BC
Royal Bank of Canada's KYNB Position: Q2 2026 in Review
Royal Bank of Canada increased its Kyntra Bio (KYNB) stake by 0.73% in Q2 2026, buying an estimated $7 and bringing the position to 138 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #7226.
Royal Bank of Canada first reported a position in KYNB in Q4 2014 and has held it in 46 quarters since. The position peaked at $6.72M in Q4 2015. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.
- Royal Bank of Canada held 138 shares of Kyntra Bio worth $1K as of Q2 2026.
- Royal Bank of Canada bought 1 Kyntra Bio share in Q2 2026, an estimated $7.
- Kyntra Bio made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7226 holding.
- Royal Bank of Canada first reported a position in Kyntra Bio in Q4 2014 and has held it in 46 quarters since.
- Royal Bank of Canada's Kyntra Bio position peaked at $6.72M in Q4 2015.
- 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.